Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
-
BUSINESS Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
-
REGULATORY Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
February 18, 2016
-
TRENDS Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
REGULATORY 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
February 16, 2016
-
TRENDS Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
REGULATORY Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
February 12, 2016
-
BUSINESS Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
-
BUSINESS Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
-
BUSINESS Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
-
REGULATORY Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
February 8, 2016
-
BUSINESS Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
February 5, 2016
-
BUSINESS Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
-
BUSINESS Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
February 3, 2016
-
BUSINESS Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
February 2, 2016
-
BUSINESS Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
-
BUSINESS Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
-
REGULATORY Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
January 28, 2016
-
TRENDS 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
TRENDS Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…